Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II

Pulmonary arterial hypertension (PAH) is an incurable chronic and progressive debilitating disease associated with significant morbidity and mortality. The World Health Organization functional class (WHO FC) at diagnosis and at follow-up remains one of the strongest predictors of survival in PAH. St...

Full description

Saved in:
Bibliographic Details
Published in:Acta Cardiologica Sinica 2020-11, Vol.36 (6), p.583-587
Main Authors: Hung, Cheng-Chung, Cheng, Chin-Chang, Huang, Wei-Chun, Lin, Kun-Chang, Kuo, Feng-Yu, Kuo, Shu-Hung, Yang, Tse-Hsuan, Liang, Hsin-Li, Mar, Guang-Yuan
Format: Article
Language:English
Subjects:
Review
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary arterial hypertension (PAH) is an incurable chronic and progressive debilitating disease associated with significant morbidity and mortality. The World Health Organization functional class (WHO FC) at diagnosis and at follow-up remains one of the strongest predictors of survival in PAH. Studies have shown improved long-term outcomes in PAH patients who received PAH-specific treatment, as monotherapy or as combination therapy, early in their disease course. Studies have also shown that without treatment, PAH rapidly deteriorates even in patients with less advanced (low risk) disease state. In this article, we review evidence from randomized controlled clinical trials to support our position on the importance of early PAH management in WHO FC II patients. The growing importance of combination therapy in the early treatment of PAH and recommendations by the most recent guidelines for the diagnosis and treatment of pulmonary hypertension are also discussed in this article.
ISSN:1011-6842
DOI:10.6515/ACS.202011_36(6).20200507A